The DOI matches its Crossref record.
Commercial challenges of protein drug delivery
Abstract
The discovery of insulin in 1922 marked the beginning of research and development to improve the means of delivering protein therapeutics to patients. From that period forward, investigators have contemplated every possible route of delivery. Their research efforts have followed two basic pathways: one path has focused on non-invasive means of delivering proteins to the body; and the second path has been primarily aimed at increasing the biological half-life of the therapeutic molecules. Thus far, the commercial successes of protein delivery by the nasal, oral and pulmonary routes have been more opportunistic rather than the application of platform technologies applicable to every protein or peptide. In several limited cases, sustained delivery of peptides and proteins has employed the use of polymeric carriers. More successes have been achieved by chemical modification using amino acid substitutions, protein pegylation or glycosylation to improve the pharmacodynamic properties of certain macromolecules. Today, commercial successes for protein and peptide delivery systems remain limited. The needle and syringe remain the primary means of protein delivery. Major hurdles remain in order to overcome the combined natural barriers of drug permeability, drug stability, pharmacokinetics and pharmacodynamics of protein therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Effects of glycosylation on the stability of protein pharmaceuticals
Solá, R. J., & Griebenow, K. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21504 · Cited by 646
Poly (2-oxazoline) s as polymer therapeutics
Luxenhofer, R., Han, Y., Schulz, A., Tong, J., He, Z., Kabanov, A. V., & Jordan, R. (2012) · Macromolecular Rapid Communications · doi:10.1002/marc.201200354 · Cited by 470
Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimize Efficacy
Solá, R. J., & Griebenow, K. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 440
Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy
Lee, S. H., Heng, D., Ng, W. K., Chan, H.-K., & Tan, R. B. H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.10.012 · Cited by 405
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Metadata
- Authors
- Brown, L. R.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2005-01
- Volume
- 2
- Issue
- 1
- Pages
- 29-42
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2030039568
- Cited by
- 208
- References
- 0
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Commercial challenges of protein drug delivery. https://app.cochat.ai/papers/10.1517/17425247.2.1.29
- The paper
- Brown, L. R. (2005). Commercial challenges of protein drug delivery. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.2.1.29
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.